Last reviewed · How we verify

NCT04447521: STREPTO

Surveillance of Non-invasive Streptococcus Pneumoniae Infections in Belgium

Status unknown Last updated 27 October 2022
What this trial tests

trial in Pneumonia in 3,600 participants. Status unknown.

Timeline
1 September 2020
Primary endpoint
1 May 2025
31 December 2025

Quick facts

Lead sponsorSciensano
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment3,600
Start date1 September 2020
Primary completion1 May 2025
Estimated completion31 December 2025
Sites1 location across Belgium

Conditions studied

Sponsor

Sciensano

Who can join

Eligibility, any sex, with Pneumonia or Otitis Media. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will conduct a prospective observational study of non-invasive S. pneumoniae infections in Belgium and characterize serotype distributions to evaluate national vaccination programs.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Non-invasive <i>Streptococcus pneumoniae</i> infections are associated with different serotypes than invasive infections, Belgium, 2020 to 2023.
    Passaris I, Depickère S, Braeye T, Mukovnikova M, et al · · 2024 · cited 7× · PMID 39512163 · DOI 10.2807/1560-7917.es.2024.29.45.2400108

Verify or expand the search:

Other recruiting trials for Pneumonia

Currently open trials in the same condition.

Other Sciensano trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04447521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing